<DOC>
	<DOCNO>NCT00002340</DOCNO>
	<brief_summary>To assess whether high dose low dose atovaquone suspension effective aerosolize pentamidine prophylaxis Pneumocystis carinii pneumonia ( PCP ) high-risk HIV-infected patient . To compare safety chronic administration three regimens patient advanced HIV disease . To determine relationship steady state atovaquone plasma concentration prophylactic efficacy PCP .</brief_summary>
	<brief_title>A Comparison Atovaquone Pentamidine Prevention Pneumocystis Carinii Pneumonia HIV-Infected Patients Who Can Take TMP/SMX</brief_title>
	<detailed_description>Patients randomize receive oral atovaquone 1 2 dos daily aerosolize pentamidine every 4 week . Treatment continue 18 month last patient enrol . Patients stratify primary secondary prophylaxis stratum base prior occurrence PCP episode .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antimicrobial agent specifically prohibit . Concurrent Treatment : Allowed : Transfusion . Patients must : HIV positivity . Prior PCP ( histologically confirm ) OR document CD4 count &lt; 200 cells/mm3 OR constitutional symptom thrush unexplained fever ( &gt; 100 F ) 2 week . No current suspect active PCP , sign active PCP chest xray . Prior intolerance TMP/SMX trimethoprim sulfacontaining regimen . Lifeexpectancy least 6 month . NOTE : Pregnant woman eligible discretion investigator . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Significant psychosis emotional disorder would preclude study compliance . Severe chronic diarrhea ( e.g. , &gt; five stools/day ) may negatively affect absorption oral medication . Unable take oral medication unable unwilling take medication food . Concurrent Medication : Excluded : Rifampin . Other investigational agent except drug available Treatment INDs expand access program . Medications likely antipneumocystis effect ( e.g. , dapsone , trimethoprim , pyrimethamine , trimetrexate , DHFR inhibitor , sulfadiazine , sulfamethoxazole , sulfonamide , primaquine , clindamycin , sulfonylureas . Corticosteroids great physiologic replacement dose 21 consecutive day . Systemic therapy CNS toxoplasmosis , Kaposi 's sarcoma , lymphoma , active malignancy , disease may decrease life expectancy confound assessment . Patients follow prior condition exclude : History severe intractable intolerance atovaquone aerosolize pentamidine . Prior hypoglycemia , pancreatitis , arrhythmia , severe hypotension associate form pentamidine . Prior enrollment protocol . Active substance abuse would preclude study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>atovaquone</keyword>
</DOC>